Cidara Therapeutics, Inc.

CDTX

Cidara Therapeutics, Inc.

CDTX

Insider Sentiment (TTM):

Last Purchase:2025-06-26Last Sale:2025-12-10Shares Purchased (TTM):0Shares Sold (TTM):10,433

Institutional Sentiment:

As of:2025-12-31Institutional Shares Owned:32,284,766Shares Outstanding:26,882,366Institutional Ownership Pct.:120.10%

Earnings Market Reaction:

Filing Date:2025-11-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	294	511	168	190	127	164	29	36	49	50	48	33
Restricted Cash Current	6	6	6	6	-	-	-	0	-	-	-	0
Available For Sale Securities Debt Securities Curr…	126	-	-	-	-	-	-	-	-	-	-	-
Accounts Receivable Net Current	2	2	2	2	2	2	7	14	3	5	26	6
Inventory Net	-	-	-	-	-	-	7	6	2	2	-	0
Prepaid Expense And Other Assets Current	15	13	13	13	28	2	3	2	4	4	6	7
Assets Of Disposal Group Including Discontinued Op…	-	-	-	0	0	0	-	9	-	-	-	-
Assets Current	443	532	189	211	157	169	47	61	58	62	79	45
Property Plant And Equipment Net	0	0	0	1	1	1	1	1	1	0	0	0
Finance Lease Right Of Use Asset	0	0	0	1	1	1	1	1	-	-	-	0
Operating Lease Right Of Use Asset	2	2	2	3	3	3	4	4	4	4	1	1
Available For Sale Securities Debt Securities Nonc…	50	-	-	-	-	-	-	-	-	-	-	-
Other Assets Noncurrent	24	0	0	0	1	0	1	0	1	1	1	1
Disposal Group Including Discontinued Operation As…	-	-	-	0	0	0	-	1	-	-	-	-
Assets	519	534	192	215	162	173	53	67	63	68	82	47
Liabilities And Stockhold…
Liabilities Current
Deferred Revenue Current	-	-	-	-	-	-	-	-	-	15	-	-
Accounts Payable Current	4	2	5	4	3	2	5	4	4	2	4	1
Accrued Liabilities Current	71	11	20	13	9	6	8	14	12	10	9	8
Accrual For Taxes Other Than Income Taxes Current	15	15	21	26	26	26	21	18	-	-	-	12
Loans Payable Current	-	-	-	-	-	-	-	-	-	-	-	0
Employee Related Liabilities Current	4	3	2	5	5	4	6	5	4	4	6	5
Finance Lease Liability Current	0	0	0	0	0	0	0	0	-	-	-	0
Operating Lease Liability Current	2	1	1	1	1	1	1	1	1	1	1	1
Liabilities Of Disposal Group Including Discontinu…	-	-	-	0	0	0	-	25	-	-	-	-
Liabilities Current	96	32	49	50	44	40	65	67	36	31	36	41
Finance Lease Liability Noncurrent	0	0	0	0	0	0	1	1	-	-	-	0
Operating Lease Liability Noncurrent	0	1	1	2	2	2	3	3	3	4	-	0
Liabilities Of Disposal Group Including Discontinu…	-	-	-	0	0	0	-	4	-	-	-	-
Liabilities	96	33	50	51	47	42	70	75	55	53	55	62
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,166	1,162	776	775	675	674	434	433	432	432	431	404
Accumulated Other Comprehensive Income Loss Net Of…	-0	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings Accumulated Deficit	-744	-660	-635	-611	-559	-543	-452	-441	-424	-416	-404	-419
Stockholders Equity	422	501	142	163	116	131	-18	-8	-6	2	15	-14
Liabilities And Stockholders Equity	519	534	192	215	162	173	53	67	63	68	82	47
Series A Convertible Voting Preferred Stock	0	0	0	0	-0	0	-	0	-	-	-	-
Series X Convertible Preferred Stock	0	0	0	0	0	0	2	0	0	0	2	0
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	100	50	50	50	50	20	200	20	200	200	200	200
Common Stock Shares Issued	29	23	12	11	7	5	5	5	5	5	5	4
Shares Outstanding	29	23	12	11	7	5	5	5	5	5	5	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	13.21%	158.22%	222.98%	5.93%	46.60%	50.85%	122.91%	123.84%	-	-	-	-
2024	1.02%	-5.19%	-6.53%	-5.84%	-10.29%	7.74%	54.16%	80.70%	44.24%	-5.17%	-8.77%	2.84%
2023	11.02%	-4.24%	-17.60%	-24.02%	0.00%	-16.08%	-17.89%	-5.17%	-17.22%	9.07%	30.76%	11.69%
2022	-	-	-	-	-	-	-	-	-	-24.48%	-18.18%	-15.38%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Liquidity Ratios
Current Ratio	4.62	16.45	3.87	4.25	3.54	4.25	0.72	0.90	1.62	1.98	2.23	1.09
Quick Ratio	4.47	16.05	3.61	3.99	2.91	4.21	0.55	0.79	1.45	1.78	2.07	0.93
Working Capital	346.98M	499.47M	140.04M	161.18M	112.43M	128.95M	-18.59M	-6.56M	22.08M	30.82M	43.83M	3.69M
Leverage & Debt
Debt to Equity	0.23	0.07	0.35	0.32	0.40	0.32	-3.96	-9.16	-9.40	21.75	3.63	-4.29
Interest Coverage TTM	-18.14	-17.17	-26.25	-30.30	-31.06	-38.92	-18.04	-13.56	-15.64	-5.69	-27.39	-137.87
Debt Ratio	0.19	0.06	0.26	0.24	0.29	0.24	1.34	1.12	0.87	0.77	0.67	1.30
Efficiency & Turnover
Asset Turnover TTM	-0.01	-0.01	-0.01	0.01	-0.29	-0.20	-0.28	0.08	1.61	1.78	1.32	1.05
Days Sales Outstanding TTM	-350.62	-414.44	-1,056.05	2,257.13	-25.22	-60.22	-318.91	838.11	13.74	19.68	69.75	31.68
Receivables Turnover TTM	-1.04	-0.88	-0.35	0.16	-14.47	-6.06	-1.14	0.44	26.56	18.54	5.23	11.52
Per Share Metrics
Diluted EPS TTM	-6.87	-7.56	-12.91	-26.75	-18.63	-24.95	-7.99	-5.25	-7.96	-2.84	-2.43	-9.61
Free Cash Flow Per Share TTM	-4.95	-8.31	-13.54	-27.82	-24.52	-27.41	-4.10	-5.25	-6.88	-0.29	-4.04	-8.19
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	10,548.46%	6,704.21%	12,432.56%	-13,811.92%	426.53%	537.71%	202.59%	-624.22%	-24.31%	-6.37%	-13.76%	-51.98%
Net Profit Margin TTM	9,969.67%	6,340.53%	11,797.61%	-13,319.76%	369.24%	479.71%	191.44%	-528.97%	-34.28%	-13.38%	-13.57%	-52.11%
Growth Metrics
Net Revenue Growth (1Y)	-94.38%	-92.19%	-91.81%	-70.59%	-131.42%	-124.81%	-120.92%	-93.27%	-	-	-	-
Net Income Growth (1Y)	51.84%	3.19%	404.50%	640.60%	238.48%	789.84%	195.12%	-31.72%	8.19%	-80.70%	-71.05%	-20.92%
EPS Growth (1Y)	-63.12%	-69.71%	61.47%	409.86%	134.00%	778.54%	155.72%	-45.44%	-15.86%	-85.19%	-74.92%	-23.17%
Calculated Values
Free Cash Flow TTM	-132.94M	-129.13M	-191.95M	-176.66M	-160.15M	-125.11M	-18.61M	-22.94M	-31.05M	-1.32M	-15.89M	-28.59M
Net Debt	-299.99M	-516.91M	-174.49M	-195.60M	-126.75M	-163.67M	-28.26M	-34.99M	-48.67M	-50.43M	-47.98M	-32.73M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-10Sale

Owner: Ward, Shane

Title: COO & CLO

Shares: 9,959

Price/Share: $220.08

Value: $2,191,776.72

Shares Owned: 25,033

Relationship: Officer

Ownership: Direct

2025-09-11Sale

Owner: Davarpanah, Nicole Negar

Title: Chief Medical Officer

Shares: 474

Price/Share: $62.86

Value: $29,795.64

Shares Owned: 31,418

Relationship: Officer

Ownership: Direct

2025-06-26Purchase

Owner: Kolchinsky, Peter, Shah R…

Title: -

Shares: 2,272,727

Price/Share: $44.00

Value: $99,999,988.00

Shares Owned: 3,365,523

Relationship: Director,TenPercentOwner

Ownership: Indirect

2025-06-03Purchase

Owner: Mineo, Chrysa

Title: -

Shares: 1,050

Price/Share: $23.44

Value: $24,612.00

Shares Owned: 3,320

Relationship: Director

Ownership: Direct

2025-03-11Sale

Owner: Ward, Shane

Title: COO & CLO

Shares: 1,664

Price/Share: $21.96

Value: $36,541.44

Shares Owned: 14,674

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-10	Ward, Shane	Officer	COO & CLO	Direct	Sale	9,959	220.08	$2,191,776.72	25,033	4
2025-09-11	Davarpanah, Nicole Negar	Officer	Chief Medical Officer	Direct	Sale	474	62.86	$29,795.64	31,418	4
2025-06-26	Kolchinsky, Peter, Shah R…	Director,TenPercentOwner	-	Indirect	Purchase	2,272,727	44.00	$99,999,988.00	3,365,523	4
2025-06-03	Mineo, Chrysa	Director	-	Direct	Purchase	1,050	23.44	$24,612.00	3,320	4
2025-03-11	Ward, Shane	Officer	COO & CLO	Direct	Sale	1,664	21.96	$36,541.44	14,674	4
2025-03-11	Tari, Leslie	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	1,773	21.96	$38,935.08	16,215	4
2024-09-11	Sandison, Taylor	Officer	Chief Medical Officer	Direct	Sale	924	11.64	$10,755.36	23,067	4
2024-09-11	Tari, Leslie	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	909	11.64	$10,580.76	17,788	4
2024-06-07	Stein, Jeffrey	Director,Officer	President & CEO	Indirect	Purchase	8,000	13.21	$105,680.00	24,580	4
2024-03-11	Sandison, Taylor	Officer	Chief Medical Officer	Direct	Sale	20,662	0.67	$13,843.54	347,095	4
2024-03-11	Ward, Shane	Officer	COO & CLO	Direct	Sale	20,473	0.67	$13,716.91	198,770	4
2024-03-11	Tari, Leslie	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	21,029	0.67	$14,089.43	258,681	4
2024-03-11	Shah, Preetam	Officer	CFO & CBO	Direct	Sale	18,931	0.67	$12,683.77	227,210	4
2023-09-11	Sandison, Taylor	Officer	Chief Medical Officer	Direct	Sale	18,793	0.95	$17,853.35	363,757	4
2023-09-11	Tari, Leslie	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	18,469	0.95	$17,545.55	275,710	4
2023-08-14	Tari, Leslie	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Purchase	10,000	0.97	$9,700.00	294,179	4
2023-08-08	Stein, Jeffrey	Director,Officer	President & CEO	Indirect	Purchase	50,000	0.96	$48,000.00	331,602	4
2023-03-27	Stein, Jeffrey	Director,Officer	President & CEO	Indirect	Purchase	50,000	1.04	$52,000.00	281,602	4
2023-03-13	Sandison, Taylor	Officer	Chief Medical Officer	Direct	Sale	7,203	1.53	$11,020.59	288,550	4
2023-03-13	Shah, Preetam	Officer	CFO & CBO	Direct	Sale	6,648	1.53	$10,171.44	148,141	4
2023-03-13	Tari, Leslie	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	7,562	1.53	$11,569.86	190,179	4
2023-03-13	Ward, Shane	Officer	COO & CLO	Direct	Sale	4,329	1.53	$6,623.37	84,576	4
2023-01-12	Tari, Leslie	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	11,814	1.20	$14,176.80	1,484	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2025-12-31

120.10%

Inst. Shares: 32,284,766

Shares Outstanding: 26,882,366

2025-09-30

120.20%

Inst. Shares: 32,312,440

Shares Outstanding: 26,882,366

2025-06-30

165.82%

Inst. Shares: 25,780,174

Shares Outstanding: 15,547,403

2025-03-31

67.42%

Inst. Shares: 9,559,109

Shares Outstanding: 14,177,743

2024-12-31

108.25%

Inst. Shares: 6,873,419

Shares Outstanding: 6,349,631

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-12-31	32,284,766	26,882,366	120.10%
2025-09-30	32,312,440	26,882,366	120.20%
2025-06-30	25,780,174	15,547,403	165.82%
2025-03-31	9,559,109	14,177,743	67.42%
2024-12-31	6,873,419	6,349,631	108.25%
2024-09-30	2,605,098	6,530,111	39.89%
2024-06-30	1,416,461	4,563,772	31.04%
2024-03-31	18,978,752	4,537,782	-
2023-12-31	20,728,379	4,371,375	-
2023-09-30	22,280,085	4,514,381	-
2023-06-30	24,707,354	4,505,813	-
2023-03-31	25,085,321	3,932,050	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Cidara Therapeutics, Inc. (CDTX) — SEC Financial Statements & Analysis

Cidara Therapeutics, Inc. (CDTX) is a biological products, (no diagnostic substances) company, incorporated in DE. Cidara Therapeutics, Inc. trades on Nasdaq as: CDTX. Based on its latest SEC filing (Form 10-Q, period ending 2025-09-30), Cidara Therapeutics, Inc. reported a -94.38% year-over-year revenue growth, a Debt-to-Equity ratio of 0.23x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -94.38%
Debt To Equity: 0.23x

Data as of 2025-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cidara Therapeutics, Inc. in?

Cidara Therapeutics, Inc. (CDTX) operates in the Biological Products, (No Diagnostic Substances) industry.

What exchange does CDTX trade on?

Cidara Therapeutics, Inc. (CDTX) trades on the Nasdaq.

Where is Cidara Therapeutics, Inc. incorporated?

Cidara Therapeutics, Inc. is incorporated in DE.